



Jörg Hüser joins Axxam as Chief Scientific Officer

June 1st, 2023 - Axxam S.p.A. (Milan/Italy), an innovative Partner Research Organization (iPRO) announced the appointment of Dr. Jörg Hüser as Chief Scientific Officer (“CSO”).

In his role, he will report to Dr. Stefan Lohmer, Chief Executive Officer, and will join the Executive Committee of the Company. He will coordinate and supervise all the scientific operations of the two sites in Italy (Milan, Naples) and the one in Germany (Constance).

Jörg brings to Axxam more than 20 years of industry experience covering the entire value chain from target discovery to early clinical development. During his tenure at Bayer AG, he held different leadership positions in Lead Discovery and Preclinical Cardiovascular Research. As the Head of Lead Discovery, he contributed to develop Bayer’s drug discovery capabilities by driving innovations in automation, bioassay, and information technologies. Overlooking more than 200 discovery projects targeting a broad spectrum of indications during this time, his team significantly impacted the company’s preclinical and clinical development pipeline. Beyond Bayer, Jörg has been recognized as one of the early drivers of the IMI initiative “European Lead Factory”, a large-scale public-private partnership operating between 2012-2022 to provide academic discovery programs access to an industrial quality library and screening. Jörg moved on to lead Heart & Vascular Disease Research. In this function he participated in formulating Bayer’s indication strategies, developed corresponding research plans and drove discovery projects from target selection to (pre-) clinical candidates.

Jörg Hüser said: *“I am very happy to join Axxam and to be part of this great team. This position will give me another exciting view on drug discovery through the lens of our clients and partners. I look forward to translating my past experiences to contributions ensuring the success of their projects. It is Axxam’s ambition to enable our partners to generate innovative solutions across all life sciences”.*

Stefan Lohmer, CEO of Axxam stated: *“We are very excited to have Jörg joining our company as part of the top management. Jörg’s leadership skills, his scientific expertise and industrial experience will be instrumental within the Executive Team to drive the company to the next level of growth. Continuing our 20-year Axxam journey, it is our goal to be the best-in-class, most innovative, biology-centric integrated research company globally, covering all steps from target assessment to lead discovery.”*

About Axxam

Axxam is an innovative Partner Research Organization (iPRO) providing integrated discovery services across the life sciences industries. Axxam is headquartered in the Milan area (Italy), with other research laboratories in Naples (Italy) as well as Constance (Germany) and business offices in Cambridge (USA), Copenhagen (Denmark) and Basel (Switzerland). Within the drug discovery disciplines, Axxam supports pharma and biotech companies, start-ups, patient foundations as well as academic groups in their journey from target assessment and hit identification to lead generation, over all therapeutic areas and target classes. Axxam’s services include assay development, high-throughput screening, hit validation and hit-to-lead. The same science-driven approach is also applied to identify new bioactive compounds for crop protection, animal health, food, beverage, pet food, cosmetic and perfume industries. For more information, please visit www.axxam.com